Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
The Zacks Analyst Blog Highlights: Home Depot, Abbott, Bristol-Myers, Activision and Marathon

The Zacks Analyst Blog Highlights: Home Depot, Abbott, Bristol-Myers, Activision and Marathon

MPC : 46.89 (-0.72%)
ABT : 84.37 (-0.62%)
ATVI : 49.08 (+0.08%)
HD : 221.02 (+0.28%)
BMY : 47.86 (+0.19%)
Top Stock Reports for Home Depot, Abbott & Bristol-Myers

Top Stock Reports for Home Depot, Abbott & Bristol-Myers

MPC : 46.89 (-0.72%)
ABT : 84.37 (-0.62%)
ATVI : 49.08 (+0.08%)
MPLX : 27.86 (-0.61%)
HD : 221.02 (+0.28%)
BMY : 47.86 (+0.19%)
The Zacks Analyst Blog Highlights: Walt Disney, AngloGold, Vipshop, Bristol-Myers and Integer

The Zacks Analyst Blog Highlights: Walt Disney, AngloGold, Vipshop, Bristol-Myers and Integer

ITGR : 76.19 (-1.46%)
AU : 21.58 (-0.51%)
VIPS : 8.02 (-5.20%)
DIS : 136.08 (+0.24%)
BMY : 47.86 (+0.19%)
The Zacks Analyst Blog Highlights: AngloGold, Bristol-Myers, Delta Air, JD.com and M/I Homes

The Zacks Analyst Blog Highlights: AngloGold, Bristol-Myers, Delta Air, JD.com and M/I Homes

AU : 21.58 (-0.51%)
MHO : 36.95 (+0.57%)
JD : 29.49 (-4.07%)
DAL : 57.96 (-0.09%)
BMY : 47.86 (+0.19%)
Keloid Treatment Market 2019 Outlook, Opportunity and Demand Analysis Report by 2024

The report scope includes market analysis on regional as well as country level. The report also provides competitive landscape covering company market shares with detailed profiling for major revenue contributing...

VRX.TO : 30.80 (-3.33%)
GALE : 0.26 (-7.14%)
AVMXY : 5.6900 (+0.71%)
NVS : 89.00 (-1.24%)
SNOA : 7.41 (+2.92%)
GSK : 40.98 (+0.71%)
BMY : 47.86 (+0.19%)
PRGO : 47.77 (-0.31%)
AstraZeneca's Imfinzi Fails in Stage IV Lung Cancer Study

AstraZeneca's (AZN) Imfinzi fails to improve overall survival in a study for previously treated stage IV non-small cell lung cancer (NSCLC) patients.

AZN : 45.41 (-0.02%)
MRK : 86.72 (-0.22%)
PFE : 35.08 (+0.60%)
BMY : 47.86 (+0.19%)
Record Revenues, Milestone Achievements Indicate Strength, Potential of Biotech Sector

Biotech and biopharma industry leaders are posting record financials and hitting milestone markers in their research and growth, good indicators of a strong market with potential for robust returns on...

CELG : 95.71 (+0.03%)
CELGZ : 0.54 (unch)
AMGN : 203.42 (-0.25%)
GNPX : 0.96 (+1.19%)
BIIB : 232.06 (-0.48%)
BMY : 47.86 (+0.19%)
Disney Whistleblower's Time in the Sun

Former Disney employee Sandra Kuba says company executives have been overstating revenues.

ITGR : 76.19 (-1.46%)
AU : 21.58 (-0.51%)
VIPS : 8.02 (-5.20%)
DIS : 136.08 (+0.24%)
BMY : 47.86 (+0.19%)
Exelixis (EXEL) Stock Up 15.2% YTD on Strong Cabometyx Sales

Exelixis (EXEL) continues to fortify its footing in the kidney cancer market on strong Cabometyx performance.

EXEL : 20.62 (-4.09%)
RHHBY : 34.5600 (-0.63%)
PFE : 35.08 (+0.60%)
BMY : 47.86 (+0.19%)
Why Bristol-Myers Squibb (BMY) is a Top Dividend Stock for Your Portfolio

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.

BMY : 47.86 (+0.19%)
4 High Earnings Yield Stocks to Bolster Your Portfolio

Earnings yield is quite effective for determining undervalued stocks.

UAL : 85.56 (+0.32%)
CMC : 15.91 (-2.99%)
DAL : 57.96 (-0.09%)
BMY : 47.86 (+0.19%)
Recession Fears Ebb on Fresh Wave of Stimulus: 5 Top Gainers

Fears of recession ebb after White House considers tax cuts for millions of workers, China unveils new interest rate reforms and Germany hints at stimulus measures.

AU : 21.58 (-0.51%)
MHO : 36.95 (+0.57%)
JD : 29.49 (-4.07%)
DAL : 57.96 (-0.09%)
BMY : 47.86 (+0.19%)
Bristol-Myer Sqb Set to Possibly Pullback After Yesterday's Rally of 1.19%

Bristol-Myer Sqb (NYSE:BMY) traded in a range yesterday that spanned from a low of $47.00 to a high of $47.63. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of...

BMY : 47.86 (+0.19%)
Watch for Bristol-Myer Sqb to Potentially Pullback After Gaining 1.19% Yesterday

Bristol-Myer Sqb (NYSE:BMY) traded in a range yesterday that spanned from a low of $47.00 to a high of $47.63. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of...

BMY : 47.86 (+0.19%)
Celgene Gets FDA Approval for Inrebic in Bone Marrow Cancer

Celgene's (CELG) oncology portfolio gets a boost with the FDA approval of Inrebic for rare bone marrow cancer.

CELG : 95.71 (+0.03%)
INCY : 85.56 (-0.59%)
XLRN : 46.21 (-2.37%)
BMY : 47.86 (+0.19%)
Roche Receives FDA Nod for Rozlytrek in ROS1-positive NSCLC

Roche's (RHHBY) lung cancer portfolio gets a boost with the approval of yet another drug, Rozlytrek, for metastatic NSCLC.

AZN : 45.41 (-0.02%)
MRK : 86.72 (-0.22%)
RHHBY : 34.5600 (-0.63%)
BMY : 47.86 (+0.19%)
Kitov Pharma Announces Significant Progress in Closing of FameWave Acquisition Deal

- Orbimed, Pontifax and Arkin Holdings to deposit $3.5 million investment in Kitov in escrow

KTOV : 0.77 (-1.91%)
BMY : 47.86 (+0.19%)
Moleculin Completes Enrollment in Early-Stage Cancer Study

Moleculin (MBRX) reaches enrollment target in a clinical study evaluating its p-STAT3 inhibitor, WP1220, as a treatment for cutaneous T-cell lymphoma, a form of skin cancer.

MRK : 86.72 (-0.22%)
SNGX : 1.06 (-2.75%)
BMY : 47.86 (+0.19%)
MBRX : 1.17 (-1.68%)
Merck's Cancer Immunotherapy Keytruda Continues to Aid Growth

Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.

AZN : 45.41 (-0.02%)
MRK : 86.72 (-0.22%)
PFE : 35.08 (+0.60%)
BMY : 47.86 (+0.19%)
Administrative Enforcement Agreement Finalized between Kitov Pharma and the Israeli Securities Authority

Israeli Investigation of Kitov and certain officers has been terminated

KTOV : 0.77 (-1.91%)
BMY : 47.86 (+0.19%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
AIZ +0.09 , WELL -0.03 , SBAC +0.11 , CCI +0.94 , SO +0.50
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar